Maria Franzén

Maria Franz is currently a PhD Candidate specializing in Pharmacometrics at Boehringer Ingelheim since February 2022. Prior experience includes work on toxicokinetics and -dynamics of chemicals in zebra fish embryos at UFZ from March 2021 to January 2022, and clinical data analysis focusing on metabolism and psychotropic drugs at LMU Klinikum der Universität München from November 2019 to February 2021. Additional roles include hazardous substance management at Argumed Consulting Group and computational biophysics modeling at Universitat Politècnica de Catalunya in 2019. Previous research at Max Planck Institute of Psychiatry involved neurophysiology related to stress-caused diseases. Maria Franz holds a Master of Science in Biochemistry from Ludwig-Maximilians-Universität München and has participated in Erasmus exchange programs in Biology, Environmental Chemistry, Chemistry, and Pharmacy. Currently engaged in the PharMetrX Graduate Research Training Program, set to conclude in September 2024.